Timing and outcomes of second‐line therapy in the era of daratumumab‐based frontline therapy in AL amyloidosis-Reference-Cited by-同舟云学术

Timing and outcomes of second‐line therapy in the era of daratumumab‐based frontline therapy in AL amyloidosis

Published:2024-08-03 Issue: Volume: Page:
ISSN:0361-8609
Container-title:American Journal of Hematology
language:en
Short-container-title:American J Hematol

Author:

Bazarbachi Abdul‐Hamid¹^ORCID,Bhutani Divaya¹^ORCID,Radhakrishnan Jai²,Mapara Markus¹,Maurer Mathew S.³,Lentzsch Suzanne¹,Chakraborty Rajshekhar¹^ORCID

Affiliation:

1. Division of Hematology/Oncology Columbia University Irving Medical Center/New York‐Presbyterian Hospital New York New York USA

2. Division of Nephrology Columbia University Irving Medical Center/New York‐Presbyterian Hospital New York New York USA

3. Division of Cardiology Columbia University Irving Medical Center/New York‐Presbyterian Hospital New York New York USA

Publisher

Wiley

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ajh.27450

Reference10 articles.

1. Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis

2. Presentation and outcome with second-line treatment in AL amyloidosis previously sensitive to nontransplant therapies

3. Treatment patterns for AL amyloidosis after frontline daratumumab, bortezomib, cyclophosphamide, and dexamethasone treatment failures

4. Venetoclax induces deep hematologic remissions in t(11;14) relapsed/refractory AL amyloidosis

5. Outcomes of venetoclax-based therapy in patients with t(11;14) light chain amyloidosis after failure of daratumumab-based therapy

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Precision medicine for multiple myeloma: The case for translocation (11;14);Cancer Treatment Reviews;2024-11